Praxis Precision Medicines, Inc. (PRAX)
NASDAQ: PRAX · Real-Time Price · USD
74.50
+1.44 (1.97%)
Nov 22, 2024, 4:00 PM EST - Market closed
PRAX Revenue
Praxis Precision Medicines had revenue of $302.00K in the quarter ending September 30, 2024, a decrease of -35.47%. This brings the company's revenue in the last twelve months to $1.61M, down -16.93% year-over-year. In the year 2023, Praxis Precision Medicines had annual revenue of $2.45M.
Revenue (ttm)
$1.61M
Revenue Growth
-16.93%
P/S Ratio
n/a
Revenue / Employee
$19,573
Employees
82
Market Cap
1.39B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Indivior | 1.18B |
Guardian Pharmacy Services | 1.17B |
Myriad Genetics | 823.60M |
Alphatec Holdings | 572.74M |
MiMedx Group | 342.80M |
Arcus Biosciences | 263.00M |
Day One Biopharmaceuticals | 101.95M |
Syndax Pharmaceuticals | 16.00M |
PRAX News
- 16 days ago - Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences - GlobeNewsWire
- 16 days ago - Praxis Precision Medicines, Inc. (PRAX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 16 days ago - Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 21 days ago - Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024 - GlobeNewsWire
- 2 months ago - Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations - GlobeNewsWire
- 2 months ago - Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine - GlobeNewsWire
- 2 months ago - Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024 - GlobeNewsWire
- 3 months ago - These Analysts Increase Their Forecasts On Praxis Precision Medicines After Q2 Results - Benzinga